Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus

Jun Hayashi, Yasunobu Kawakami, Atsuko Nabeshima, Yasuhiro Kishihara, Norihiro Furusyo, Yasunori Sawayama, Naoko Kinukawa, Seizaburo Kashiwagi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

To compare hepatitis C virus (HCV) RNA levels determined by branched DNA probe assay and by competitive polymerase chain reaction (PCR) as predictive markers of the response to interferon for treatment of patients with chronic HCV infection, we studied data on 140 patients treated for six months with natural interferon-α. Serum samples were tested for HCV RNA by PCR. HCV RNA was grouped into four genotypes by PCR with type-specific primers, and HCV RNA level was measured by branched DNA probe assay and by competitive PCR. HCV RNA was detected in all patients prior to initiation of the treatment. A complete response, sustained elimination of HCV RNA, occurred in 51 patients (36.4%). With multiple logistic regression analysis assessment, when using competitive PCR, a low level of HCV RNA (P < 0.0001), younger age (P = 0.0054) and genotype 2a and 2b (P < 0.0158) were significant predictive markers for a complete response to interferon treatment. When using branched DNA probe assay, a low level of HCV RNA (P < 0.0001) and age (P = 0.0089) were predictive markers, but genotype was not. The branched DNA probe assay had a narrower linear range for quantitation of HCV RNA level than competitive PCR. In conclusion, HCV RNA level determined by branched DNA probe assay proved to be useful for prediction of effects of interferon and it is cost effective as a marker of complete response to interferon treatment for patients with chronic HCV infection.

Original languageEnglish
Pages (from-to)384-391
Number of pages8
JournalDigestive Diseases and Sciences
Volume43
Issue number2
DOIs
Publication statusPublished - Mar 31 1998

Fingerprint

Branched DNA Signal Amplification Assay
DNA Probes
Chronic Hepatitis C
Hepacivirus
Interferons
RNA
Polymerase Chain Reaction
Genotype
Virus Diseases
DNA-Directed RNA Polymerases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus. / Hayashi, Jun; Kawakami, Yasunobu; Nabeshima, Atsuko; Kishihara, Yasuhiro; Furusyo, Norihiro; Sawayama, Yasunori; Kinukawa, Naoko; Kashiwagi, Seizaburo.

In: Digestive Diseases and Sciences, Vol. 43, No. 2, 31.03.1998, p. 384-391.

Research output: Contribution to journalArticle

Hayashi, Jun ; Kawakami, Yasunobu ; Nabeshima, Atsuko ; Kishihara, Yasuhiro ; Furusyo, Norihiro ; Sawayama, Yasunori ; Kinukawa, Naoko ; Kashiwagi, Seizaburo. / Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus. In: Digestive Diseases and Sciences. 1998 ; Vol. 43, No. 2. pp. 384-391.
@article{9a332e5352e44c81b905c80a496c2b34,
title = "Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus",
abstract = "To compare hepatitis C virus (HCV) RNA levels determined by branched DNA probe assay and by competitive polymerase chain reaction (PCR) as predictive markers of the response to interferon for treatment of patients with chronic HCV infection, we studied data on 140 patients treated for six months with natural interferon-α. Serum samples were tested for HCV RNA by PCR. HCV RNA was grouped into four genotypes by PCR with type-specific primers, and HCV RNA level was measured by branched DNA probe assay and by competitive PCR. HCV RNA was detected in all patients prior to initiation of the treatment. A complete response, sustained elimination of HCV RNA, occurred in 51 patients (36.4{\%}). With multiple logistic regression analysis assessment, when using competitive PCR, a low level of HCV RNA (P < 0.0001), younger age (P = 0.0054) and genotype 2a and 2b (P < 0.0158) were significant predictive markers for a complete response to interferon treatment. When using branched DNA probe assay, a low level of HCV RNA (P < 0.0001) and age (P = 0.0089) were predictive markers, but genotype was not. The branched DNA probe assay had a narrower linear range for quantitation of HCV RNA level than competitive PCR. In conclusion, HCV RNA level determined by branched DNA probe assay proved to be useful for prediction of effects of interferon and it is cost effective as a marker of complete response to interferon treatment for patients with chronic HCV infection.",
author = "Jun Hayashi and Yasunobu Kawakami and Atsuko Nabeshima and Yasuhiro Kishihara and Norihiro Furusyo and Yasunori Sawayama and Naoko Kinukawa and Seizaburo Kashiwagi",
year = "1998",
month = "3",
day = "31",
doi = "10.1023/A:1018874910195",
language = "English",
volume = "43",
pages = "384--391",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus

AU - Hayashi, Jun

AU - Kawakami, Yasunobu

AU - Nabeshima, Atsuko

AU - Kishihara, Yasuhiro

AU - Furusyo, Norihiro

AU - Sawayama, Yasunori

AU - Kinukawa, Naoko

AU - Kashiwagi, Seizaburo

PY - 1998/3/31

Y1 - 1998/3/31

N2 - To compare hepatitis C virus (HCV) RNA levels determined by branched DNA probe assay and by competitive polymerase chain reaction (PCR) as predictive markers of the response to interferon for treatment of patients with chronic HCV infection, we studied data on 140 patients treated for six months with natural interferon-α. Serum samples were tested for HCV RNA by PCR. HCV RNA was grouped into four genotypes by PCR with type-specific primers, and HCV RNA level was measured by branched DNA probe assay and by competitive PCR. HCV RNA was detected in all patients prior to initiation of the treatment. A complete response, sustained elimination of HCV RNA, occurred in 51 patients (36.4%). With multiple logistic regression analysis assessment, when using competitive PCR, a low level of HCV RNA (P < 0.0001), younger age (P = 0.0054) and genotype 2a and 2b (P < 0.0158) were significant predictive markers for a complete response to interferon treatment. When using branched DNA probe assay, a low level of HCV RNA (P < 0.0001) and age (P = 0.0089) were predictive markers, but genotype was not. The branched DNA probe assay had a narrower linear range for quantitation of HCV RNA level than competitive PCR. In conclusion, HCV RNA level determined by branched DNA probe assay proved to be useful for prediction of effects of interferon and it is cost effective as a marker of complete response to interferon treatment for patients with chronic HCV infection.

AB - To compare hepatitis C virus (HCV) RNA levels determined by branched DNA probe assay and by competitive polymerase chain reaction (PCR) as predictive markers of the response to interferon for treatment of patients with chronic HCV infection, we studied data on 140 patients treated for six months with natural interferon-α. Serum samples were tested for HCV RNA by PCR. HCV RNA was grouped into four genotypes by PCR with type-specific primers, and HCV RNA level was measured by branched DNA probe assay and by competitive PCR. HCV RNA was detected in all patients prior to initiation of the treatment. A complete response, sustained elimination of HCV RNA, occurred in 51 patients (36.4%). With multiple logistic regression analysis assessment, when using competitive PCR, a low level of HCV RNA (P < 0.0001), younger age (P = 0.0054) and genotype 2a and 2b (P < 0.0158) were significant predictive markers for a complete response to interferon treatment. When using branched DNA probe assay, a low level of HCV RNA (P < 0.0001) and age (P = 0.0089) were predictive markers, but genotype was not. The branched DNA probe assay had a narrower linear range for quantitation of HCV RNA level than competitive PCR. In conclusion, HCV RNA level determined by branched DNA probe assay proved to be useful for prediction of effects of interferon and it is cost effective as a marker of complete response to interferon treatment for patients with chronic HCV infection.

UR - http://www.scopus.com/inward/record.url?scp=0031940864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031940864&partnerID=8YFLogxK

U2 - 10.1023/A:1018874910195

DO - 10.1023/A:1018874910195

M3 - Article

C2 - 9512135

AN - SCOPUS:0031940864

VL - 43

SP - 384

EP - 391

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 2

ER -